Genetic sequencing company Oxford Nanopore Technologies made a stellar debut on the London Stock Exchange Thursday, with shares surging 47% to a valuation of almost 5 billion pounds, or $6.7 billion. The University of Oxford spin-off develops technology for real-time DNA sequencing, which has been used extensively to identify and track Covid-19 variants. “We are living on the cusp of the genomic era,” said chief executive Gordon Sanghera in a statement.
Read More